gene

C1QA

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about C1QA: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

706Connections

8Hypotheses

12Analyses

50Outgoing

50Incoming

5Experiments

Summary

C1QA is a gene implicated in neurodegeneration research. Key relationships include: activates, associated with, expressed in. Associated with AD, ALI, ALS. Connected to 167 entities in the SciDEX knowledge graph.

View on Wiki →

🧬 Gene Info

Gene Symbol	C1QA
Full Name	Complement Component 1, Q Subunit A
Chromosome	1p36.33
Protein Type	Signaling Protein
Target Class	Signaling Protein
Function	Mechanism
Mechanism of Action	Complement cascade inhibitor or antibody-mediated neutralization
Druggability	Low (0.41)
Clinical Stage	Phase II
Amino Acids	245 aa
Pathways	Complement, Complement system, Synaptic pruning, complement activation
UniProt ID	P02787
NCBI Gene ID	712
Ensembl ID	ENSG00000196954
OMIM	120550
GeneCards	C1QA
Human Protein Atlas	C1QA
Associated Diseases	AD, ALI, ALS, Aging, Alzheimer
Known Drugs/Compounds	ANX005
Interactions	SPP1, GRN, C1QC, CTSB, C1Q, CLU
SciDEX Target	View Target Profile (7 clinical trials)
SciDEX Hypotheses	Complement C1q Suppression as Mechanism Linking Ex Complement C1q Mimetic Decoy Therapy Complement C1q Subtype Switching (+3 more)
KG Connections	705 knowledge graph edges
Databases	GeneCards HPA STRING

🧬 3D Structure: C1QA — PDB 1PK6 Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    C1QA["C1QA"]
    C1QA -->|"regulates"| complement_activation["complement activation"]
    C1QA -->|"expressed in"| _middle_temporal_gyrus__spiny_["'middle temporal gyrus'_spiny_L3"]
    C1QA -->|"expressed in"| _middle_temporal_gyrus__aspiny["'middle temporal gyrus'_aspiny_L3"]
    C1QA -->|"activates"| Alzheimer["Alzheimer"]
    C1QA -->|"activates"| Dementia["Dementia"]
    C1QA -->|"activates"| Als["Als"]
    C1QA -->|"activates"| Inflammation["Inflammation"]
    C1QA -->|"activates"| Neuroinflammation["Neuroinflammation"]
    C1QA -->|"activates"| Anxiety["Anxiety"]
    h_5a55aabc["h-5a55aabc"] -->|"target for"| C1QA
    h_1fe4ba9b["h-1fe4ba9b"] -->|"target for"| C1QA
    CTSB["CTSB"] -->|"activates"| C1QA
    C1Q["C1Q"] -->|"activates"| C1QA
    SPP1["SPP1"] -->|"activates"| C1QA
    SPI1["SPI1"] -->|"expressed in"| C1QA
    APOE["APOE"] -->|"activates"| C1QA
    MMP9["MMP9"] -.biomarker for.-> C1QA

Outgoing (482)

Target	Relation	Type	Str
ATHEROSCLEROSIS	associated_with	entity	0.90
Hallmark_Complement	involved_in	pathway	0.90
Complement Cascade	activates	pathway	0.90
Atherosclerotic Plaques	biomarker_for	disease	0.85
synapses	associated_with	cell_type	0.85
Alzheimer'S Disease	biomarker_for	disease	0.85
Atherosclerosis	biomarker_for	disease	0.85
Atherosclerosis	risk_factor_for	disease	0.85
Microglial Synaptic Elimination	mediates	process	0.85
biomarker_for	biomarker_for	phenotype	0.80
A1 astrocyte	inhibits	cell_type	0.80
Ischemic Stroke	risk_factor_for	disease	0.78
SLC17A7	loss_linked_to	gene	0.75
GFAP	astrocyte_response_linked_to	protein	0.75
excitatory neurons	expressed_in	cell_type	0.75
Als	activates	disease	0.75
neurons	expressed_in	cell_type	0.75
complement activation	regulates	pathway	0.70
C1Q	activates	gene	0.70
"middle temporal gyrus"_spiny_L3	expressed_in	cell_type	0.70
"middle temporal gyrus"_aspiny_L3	expressed_in	cell_type	0.70
"middle temporal gyrus"_spiny_L5	expressed_in	cell_type	0.70
complement cascade	participates_in	pathway	0.70
Phagocytosis	activates	pathway	0.70
Complement	activates	pathway	0.70
COMPLEMENT	activates	gene	0.70
macrophages	treats	cell_type	0.70
Alzheimer	activates	disease	0.65
Dementia	activates	disease	0.65
Atherosclerosis	associated_with	disease	0.65
Stroke	associated_with	disease	0.65
Ms	associated_with	disease	0.65
Inflammation	activates	disease	0.65
Neuroinflammation	activates	disease	0.65
Anxiety	activates	disease	0.65
Neurodegeneration	associated_with	disease	0.65
Multiple Sclerosis	associated_with	disease	0.65
Als	associated_with	disease	0.65
Aging	associated_with	disease	0.65
Atherosclerosis	activates	disease	0.65
Stroke	activates	disease	0.65
Anxiety	contributes_to	disease	0.65
Inflammation	contributes_to	disease	0.65
Neuroinflammation	contributes_to	disease	0.65
Diabetes	expressed_in	disease	0.65
Inflammation	associated_with	disease	0.65
Senescence	associated_with	disease	0.65
Neuroinflammation	associated_with	disease	0.65
Inflammation	therapeutic_target	disease	0.65
Alzheimer	therapeutic_target	disease	0.65

Incoming (224)

Source	Relation	Type	Str
C4B	pathway_partner	gene	0.90
SPP1	upregulates	gene	0.90
h-5a55aabc	targets_gene	hypothesis	0.90
h-1fe4ba9b	targets_gene	hypothesis	0.90
h-seaad-5b3cb8ea	targets_gene	hypothesis	0.90
h-a8165b3b	targets_gene	hypothesis	0.90
h-f19b8ac8	targets_gene	hypothesis	0.90
h-494861d2	targets_gene	hypothesis	0.90
SPI1	regulates	entity	0.85
h-5a55aabc	targets	hypothesis	0.80
h-1fe4ba9b	targets	hypothesis	0.80
TREM2	co-expressed_with	gene	0.80
C1Q	co_mentioned_with	gene	0.80
SLC17A7	synapse_loss_linked_to	gene	0.75
h-494861d2	targets	hypothesis	0.70
CTSB	activates	gene	0.60
GBM	associated_with	gene	0.60
C1Q	activates	gene	0.60
SPP1	activates	gene	0.60
SPI1	expressed_in	gene	0.60
CR1	associated_with	gene	0.60
APOE	activates	gene	0.60
MMP9	biomarker_for	gene	0.60
PI3K	expressed_in	gene	0.60
AKT	expressed_in	gene	0.60
C1Q	expressed_in	gene	0.60
CD4	associated_with	gene	0.60
LMNA	activates	gene	0.60
CCL20	activates	gene	0.60
CLN3	therapeutic_target	gene	0.60
CXCL10	associated_with	gene	0.60
GRN	activates	gene	0.60
C1QC	activates	gene	0.60
NLRP3	therapeutic_target	gene	0.60
CX3CR1	therapeutic_target	gene	0.60
GPNMB	therapeutic_target	gene	0.60
P2RY12	therapeutic_target	gene	0.60
TAU	therapeutic_target	gene	0.60
DRD1	therapeutic_target	gene	0.60
APOE	associated_with	gene	0.60
RAMP1	biomarker_for	gene	0.60
C1QB	associated_with	gene	0.60
TYROBP	associated_with	gene	0.60
CSF1R	associated_with	gene	0.60
C1QB	regulates	gene	0.60
C1R	regulates	gene	0.60
SIRPA	regulates	gene	0.60
C1QC	regulates	gene	0.60
C1S	regulates	gene	0.60
MERTK	regulates	gene	0.60

Targeting Hypotheses (8)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Complement C1q Suppression as Mechanism Linking Exercise Pla	0.560	neurodegeneration	What are the specific circulating factor
C1QA/C1QB Subunit-Specific Inhibition to Block Aberrant PV I	0.497	neurodegeneration	Are interneuron oscillation deficits com
Complement C1q Mimetic Decoy Therapy	0.479	neurodegeneration	Synaptic pruning by microglia in early A
Complement C1QA Inhibition Synergizes with PV Interneuron Mo	0.473	neurodegeneration	What molecular mechanisms underlie the d
Complement C1q Subtype Switching	0.437	neurodegeneration	4R-tau strain-specific spreading pattern

Complement C1QA Spatial Gradient in Cortical Layers	0.428	Alzheimer's Disease	SEA-AD Gene Expression Profiling — Allen
Complement-Mediated Synaptic Protection	0.410	neurodegeneration	Neuroinflammation and microglial priming
Complement-Mediated Synaptic Pruning Dysregulation	0.398	neurodegeneration	Gene expression changes in aging mouse b

Mentioning Analyses (12)

Scientific analyses that reference this entity

Experiments (5)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated Neurotoxic	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$5,460,000
Experiment: Autoimmune Hypothesis Testing in AD	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$5,460,000
cGAS-STING Pathway Validation Study in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$7,100,000
s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice with engin	falsification	Neuroinflammation	0.400	0.50	mouse	proposed	$200,000
Proposed experiment from debate on Synaptic pruning by microglia in ea	falsification	Alzheimer's Disease	0.400	0.50	mouse	proposed	$200,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Prolonged anesthesia induces neuroinflammation and complement-mediated microglia [PMID:36600274]	Xu F, Han L, Wang Y, Deng D, Ding Y, Zha	BMC Med	2023	2
Perivascular cells induce microglial phagocytic states and synaptic engulfment v [PMID:36747024]	De Schepper S, Ge JZ, Sierksma A, Crowle	Nat Neurosci	2023	2
An integrative analysis of single-cell and bulk transcriptome and bidirectional [PMID:38179058]	Cui HK, Tang CJ, Gao Y, Li ZA, Zhang J,	Front Immunol	2023	2
Early complement genes are associated with visual system degeneration in multipl [PMID:31289819]	Fitzgerald KC, Kim K, Smith MD, Aston SA	Brain	2019	1
Phosphoproteomics uncovers a neuroimmune perspective on trigeminal neuralgia: se [PMID:41853292]	Zhai X, Lin X, Zhang L, Ren Y, Miao H, M	Frontiers in immunology	2026	0
Proteomic Signature in Men with Central Serous Chorioretinopathy. [PMID:41641862]	Chambon C, Picard E, Zola M, Aichedo S,	Journal of proteome research	2026	0
Machine Learning and Blood-Targeted Proteomics Enable Early Prediction and Etiol [PMID:41683823]	Starodubtseva N, Tokareva A, Kononikhin	International journal of molec	2026	0
Club cell RhoA activation amplifies allergic airway inflammation by regulating e [PMID:41633491]	Tu W, Wu M, Wan R, Alphonse M, Gu W, Gho	The Journal of allergy and cli	2026	0
Identifying the hub genes in macrophage infiltration and verifying of the role o [PMID:41730938]	Tang L, Xu Y, Nong Z, Li F, Pan L	Scientific reports	2026	0
Sustained inhibitory dysfunction in complement component C1qa-deficient mice und [PMID:41544964]	Righes Marafiga J, Vu T, Bowlus J, Barab	Progress in neurobiology	2026	0
Synaptic pruning genes networks in Alzheimer's disease: correlations with neurop [PMID:40515808]	Sanfilippo C, Castrogiovanni P, Imbesi R	GeroScience	2026	0
Robust characterization and interpretation of rare pathogenic cell populations f [PMID:41547856]	Zhang X, Yu Z, Hao G, Yao Q, Hu Y et al.	Nat Commun	2026	0
Structural signature of plasma proteins classifies the status of Alzheimer's dis [PMID:41760935]	Son A, Kim H, Diedrich JK, Bamberger C,	Nat Aging	2026	0
Molecular Insights Into Canine Hepatocellular Carcinoma: A Cross-Species Transcr [PMID:41664952]	Arif M, Hasan MN, Nozaki N, Ide Y, Akiya	Mol Carcinog	2026	0
Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acid [PMID:40533746]	["Sanadgol N", "Abedi M", "Hashemzaei M"	Journal of nanobiotechnology	2025	0
Sex-Specific Molecular Architecture of Microglia-Mediated Neuronal Pruning Acros [PMID:41324815]	Sanfilippo C, Castrogiovanni P, Imbesi R	Molecular neurobiology	2025	0
Proteomic discoveries in hypermobile Ehlers-Danlos syndrome reveal insights into [PMID:40972649]	Griggs M, Daylor V, Petrucci T, Weintrau	ImmunoHorizons	2025	0
The dopamine analogue CA140 alleviates AD pathology, neuroinflammation, and resc [PMID:39129007]	Chae S, Lee HJ, Lee HE, Kim J, Jeong YJ,	Journal of neuroinflammation	2024	0
Identification of crosstalk genes and immune characteristics between Alzheimer's [PMID:39188714]	An W, Zhou J, Qiu Z, Wang P, Han X, Chen	Frontiers in immunology	2024	0
Single-cell RNA sequencing reveals distinct immunology profiles in human keloid. [PMID:35990663]	["Feng C", "Shan M", "Xia Y", "Zheng Z",	Frontiers in immunology	2022	0

C1QA

Understanding Entity Pages

Summary

Wiki Pages (21)

C1QA Gene

cognitive-reserve-cbs-psp

Section 153: Virtual Reality Therapy Protocols in CBS/PSP

Granulovacuolar Bodies: Neuronal Defense Mechanism Against Tau Pathology

Microglia Activation Mechanism

Complement Activation in Corticobasal Degeneration

Pathway Diagram

Outgoing (482)

Incoming (224)

Targeting Hypotheses (8)

Mentioning Analyses (12)

What are the specific circulating factors in exercise-conditioned plasma that me

Do these mechanistic hypotheses from the SEA-AD Atlas bundle explain layer-speci

Do these mechanistic hypotheses explain layer-specific synaptic vulnerability in

Mechanistic validation of SEA-AD differential expression hypotheses: Complement

How does sevoflurane-induced NF-κB activation specifically trigger complement ca

What determines the selectivity of complement-mediated synaptic elimination in p

What are the specific molecular mechanisms by which C1Q components drive atheros

Neuroinflammation and microglial priming in early Alzheimer's Disease

Gene expression changes in aging mouse brain predicting neurodegenerative vulner

SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas

Synaptic pruning by microglia in early AD

4R-tau strain-specific spreading patterns in PSP vs CBD

Experiments (5)

Related Papers (20)

C1QA

Understanding Entity Pages

Summary

Wiki Pages (21)

C1QA Gene

cognitive-reserve-cbs-psp

Section 153: Virtual Reality Therapy Protocols in CBS/PSP

Granulovacuolar Bodies: Neuronal Defense Mechanism Against Tau Pathology

Microglia Activation Mechanism

Complement Activation in Corticobasal Degeneration

nct02605785-tau-pet-psp

Tau Proteostasis and Clearance Across 4R-Tauopathies

Davunetide (AL-108) PSP Trial

section-181-advanced-music-rhythm-therapy-cbs-psp

Microglia

Advanced Metal Chelation Therapy in CBS/PSP

PROTAC Therapy for Parkinson's Disease

Microglia and neuroinflammation in Alzheimer's Disease

Computational Models of Tau Propagation in Progressive Supranuclear Palsy

Neuroimmune Dysfunction in Frontotemporal Dementia

FNP-223 PROSPER Trial - Phase 2 in Progressive Supranuclear Palsy

Virtual Reality Therapy for CBS/PSP Gait Training

oga-inhibition-tau

section-155-art-therapy-creative-arts-therapies-cbs-psp

Microglia-Neuron Metabolic Cross-Talk in Neurodegeneration

Pathway Diagram

Outgoing (482)

Incoming (224)

Targeting Hypotheses (8)

Mentioning Analyses (12)

What are the specific circulating factors in exercise-conditioned plasma that me

Do these mechanistic hypotheses from the SEA-AD Atlas bundle explain layer-speci

Do these mechanistic hypotheses explain layer-specific synaptic vulnerability in

Mechanistic validation of SEA-AD differential expression hypotheses: Complement

How does sevoflurane-induced NF-κB activation specifically trigger complement ca

What determines the selectivity of complement-mediated synaptic elimination in p

What are the specific molecular mechanisms by which C1Q components drive atheros

Neuroinflammation and microglial priming in early Alzheimer's Disease

Gene expression changes in aging mouse brain predicting neurodegenerative vulner

SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas

Synaptic pruning by microglia in early AD

4R-tau strain-specific spreading patterns in PSP vs CBD

Experiments (5)

Related Papers (20)